Table of Contents -
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Secondary Research Methodology
3.1.3 Market Share Analysis
3.1.4 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing application of unnatural amino acids in Pharmaceuticals (Impact Weightage 40%)
4.2.2 Increasing prevalence of chronic diseases (Impact Weightage 35%)
4.2.3 Increasing demands for new and advanced drugs (Impact Weightage 25%)
4.3 Restraints
4.3.1 Stringent Government Regulation (Impact Weightage 60%)
4.3.2 Lack of research and development sector in underdeveloped region (Impact Weightage 40%)
4.4 Opportunity
4.5 Mega Trends
4.6 Macroeconomic indicators
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-sales Monitoring
?
5.2 Porters Five Forces Model
5.2.1 Bargaining power of suppliers (Medium to High)
5.2.2 Bargaining Power of Buyers (Low to Medium)
5.2.3 Threat of New Entrants (Low to Medium)
5.2.4 Threat of Substitutes (Medium)
5.2.5 Intensity of Rivalry (High)
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
6 Global Unnatural Amino Acids Market, by Type
6.1 Introduction
6.2 D-Amino Acids & Derivatives
6.3 DL-Amino Acids & Derivatives
6.4 ?-Amino Acids & Derivatives
6.5 Cyclic Amino Acids & Derivatives
6.6 L-Amino Acid Derivatives
6.7 Gamma-Amino Butyric Acid
6.8 Gamma-Amino-Beta-Hydroxybutyric Acid
6.9 Synthetic -Amino Acids
7 Global Unnatural Amino Acids Market, by Applications
7.1 Introduction
7.2 Liver Diseases
7.3 Cancer
7.4 Inflammatory Disease
7.5 Genetic Diseases
8 Global Unnatural Amino Acids Market, By End User
8.1 Introduction
8.2 Pharmaceutical & Biotechnological Companies
8.3 Research Laboratories
8.4 Academic Institutes
9 Global Unnatural Amino Acids Market, By Region
9.1 Introduction
9.2 Americas
9.2.1 U.S.
9.2.2 Canada
9.2.3 South America
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 U.K
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Western Europe
9.3.7 Eastern Europe
9.4 Asia Pacific
9.4.1 India
9.4.2 China
9.4.3 Jpan
9.4.4 Australia
9.4.5 republic of korea
9.4.6 rest of asia pacific
9.5 The Middle East and Africa
10 Competitive Landscape
10.1 Introduction
10.2 Company Share Analysis
11 Company Profiles
11.1 Aminologics Co
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Stratergy
11.1.5 Key Developments
11.2 BASF SE
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Stratergy
11.2.5 Key Developments
11.3 Sigma-Aldrich Corporation
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Stratergy
11.3.5 Key Developments
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Stratergy
11.4.5 Key Developments
11.5 Bayer
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Stratergy
11.5.5 Key Developments
11.6 GlaxoSmithKline plc
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Stratergy
11.6.5 Key Developments
11.7 Abbott
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Stratergy
11.7.5 Key Developments
11.8 AstraZeneca
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Stratergy
11.8.5 Key Developments
11.9 Pfizer
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Stratergy
11.9.5 Key Developments
11.1 AbbVie
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Stratergy
11.10.5 Key Developments
11.11 Enzo-Life-Sciences , Inc
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Products
11.11.4 Stratergy
11.11.5 Key Developments
11.12 CU Chemie Uetikon
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Products
11.12.4 Stratergy
11.12.5 Key Developments
11.13 Yoneyama Yakuhin Kogyo
11.13.1 Company Overview
11.13.2 Financials
11.13.3 Products
11.13.4 Stratergy
11.13.5 Key Developments
11.14 Miat S.p.A.
11.14.1 Company Overview
11.14.2 Financials
11.14.3 Products
11.14.4 Stratergy
11.14.5 Key Developments
11.15 AnaSpec Inc.
11.15.1 Company Overview
11.15.2 Financials
11.15.3 Products
11.15.4 Stratergy
11.15.5 Key Developments
11.16 Ajinomoto Co., Inc.
11.16.1 Company Overview
11.16.2 Financials
11.16.3 Products
11.16.4 Stratergy
11.16.5 Key Developments
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO's View Point
12.1.2 Unmet Needs
12.2 Key companies to watch
13 Appendix
13.1 Discussion Blue Print